VEGFA and carcinoma: This can explain why in some patients bevacizumab could be a highly effective antiangiogenic agent - those in which the vast majority of the VEGF in their carcinomas is VEGFxxx (the proangiogenic family), whereas in most, those with significant VEGFxxxb expression, bevacizumab may be less effective.